Under the partnership, SCIENION's CL2 sciREADER system will be integrated with the PictArray SARS-CoV-2 Serology Test, which will soon begin clinical testing for FDA EUA market clearance
BERLIN, GERMANY - September 28, 2021 - SCIENION, a BICO company, today announced that it has entered into a strategic collaboration with diagnostic biotechnology company Pictor Limited to commercialize a high-throughput SARS-CoV-2 antibody testing system. Under the collaboration, the two companies will integrate SCIENION's CL2 sciREADER system with the PictArray SARS-CoV-2 Serology Test to create the only platform capable of testing both anti-nucleocapsid and anti-spike antibodies in one reaction. This analysis will be critical to support the sustained fight against the pandemic by measuring the level of herd immunity of the population through natural infections and vaccination.
"As COVID-19 remains a widespread problem, measuring antibody levels in different populations is critical for public health authorities to prevent the emergence of new variants," said Dr. Holger Eickhoff, co-founder and CEO of SCIENION GmbH. "We are honored to work with Pictor to further develop this important technology."
The combined system will provide a highly automated, miniaturized multiplex immunoassay assay in a 96-well plate format that enables rapid analysis of patient antibody levels. The system also uses software developed by Pictor Ltd. that creates a risk score for individuals to determine the likelihood of COVID-19 infection.
"We are very excited about this strategic collaboration with SCIENION," said Thomas Schlumpberger, Chief Executive Officer of Pictor Ltd. "By leveraging the high performance and accuracy of the sciREADER colormetric, Pictor can bring multiplexed antibody testing for SARS-CoV-2 to market with high throughput, high performance and at low cost. We are keen to provide insights into the epidemiological spread of the virus to support control and prevention measures"
The PictArray SARS-CoV-2 Serology Test will enter clinical trials in September 2021 with the goal of obtaining FDA Emergency Use Authorization (EUA) and launching in early 2022. The companies also plan to seek a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) for use in the United Kingdom and the European Union.
Companies interested in using the PictArray SARS-CoV-2 Serology Test for antibody testing can learn more at www.pictordx.com/news/
BICO Press Office
Riley Munks, PR Manager (650) 863-6699
Alyssa DOrazio, PR Manager (617) 634-9601
Founded in 2001, SCIENION is a recognized specialist in precision liquid handling in the picoliter to microliter range, enabling applications from research to high-throughput assay production in diagnostics and life sciences. As a provider of complete solutions for the dynamically growing demand for miniaturization and multiplex analysis, SCIENION offers a unique portfolio of automated precision dispensing systems, readers, consumables, assay development and contract manufacturing. The company has two sites in Germany, Dortmund and Berlin, as well as subsidiaries in Arizona, USA, Chichester, UK, and Cellenion in Lyon, France.
SCIENION is part of BICO, the world's leading bio-convergence company providing technologies, products and services to create, understand and control biology.
Pictor was founded in 2005 by entrepreneurial scientists Dr. Anand Kumble and Dr. Sarita Kumble, who retired in 2017. Pictor has since expanded and now employs 25 people in the US, New Zealand, Europe and India. In August 2020, Pictor formed Pictor Inc. in the United States and appointed Dr. Thomas Schlumpberger as its new CEO, based in San Francisco. The previous CEO, New Zealand serial entrepreneur Howard Moore, is now COO. www.pictordx.com
Founded in 2016, BICO (formerly CELLINK) is the world's leading bio-convergence company. By combining various technologies such as robotics, artificial intelligence, informatics and 3D bioprinting with biology, we enable our customers to improve people's health and lives.
Focusing on the application areas of bioprinting, multi-omics, cell line development and diagnostics, the company develops and markets innovative technologies that enable life science researchers to 3D culture cells, perform high-throughput drug screening and print human tissue and organs for the medical, pharmaceutical and cosmetics industries. We are creating the future of health.
The Group's products are trusted by more than 2,000 laboratories, including all 20 leading pharmaceutical companies, are used in more than 65 countries and have been cited in more than 1,850 publications. BICO is listed on Nasdaq Stockholm under BICO. www.bico.com